Skip to content
value.today

Otonomy: peers

Change the peers

Otonomy beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Otonomy, Seer, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Otonomy, PMV Pharmaceuticals, Inc., Seer, Inc., Tonix Pharmaceuticals Holding Corp., Vaxart, Inc., Rani Therapeutics Holdings, Inc., LENZ Therapeutics, Inc., NRX Pharmaceuticals, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureOtonomybase
OTIC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
PMV Pharmaceuticals, Inc.
PMVP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Seer, Inc.
SEER · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Tonix Pharmaceuticals Holding Corp.
TNXP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Vaxart, Inc.
VXRT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Rani Therapeutics Holdings, Inc.
RANI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
LENZ Therapeutics, Inc.
LENZ · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NRX Pharmaceuticals, Inc.
NRXP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$113 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one4th of 8$113 MOct 9, 2026 · Market data5th of 8$115 MAug 1, 2026 · Market data3rd of 8$111 MOct 20, 2026 · Market data6th of 8$117 MOct 22, 2026 · Market data2nd of 8$110 MSep 22, 2026 · Market data7th of 8$110 MOct 30, 2026 · Market data8th of 8$118 MOct 30, 2026 · Market data1st of 8$113 M8 ranked
Revenue (Better neither way: ranked highest first)————$17 MFY2025 · SEC3rd of 6$13 MFY2025 · SEC4th of 6$237 MFY2025 · SEC1st of 6$2 MFY2025 · SEC5th of 6$19 MFY2025 · SEC2nd of 6$1 MFY2025 · SEC6th of 6$15 M6 ranked
Net income (Higher is better)——$-78 MFY2025 · SEC5th of 7$-74 MFY2025 · SEC4th of 7$-124 MFY2025 · SEC7th of 7$16 MFY2025 · SEC1st of 7$-30 MFY2025 · SEC3rd of 7$-82 MFY2025 · SEC6th of 7$-29 MFY2025 · SEC2nd of 7$-74 M7 ranked
Employees (Better neither way: ranked highest first)——35As on 2021 · Profile4th of 560As on 2019 · Profile3rd of 5——15As on 2021 · Profile5th of 569December 31, 2025 · Profile2nd of 5152December 31, 2025 · Profile1st of 5——605 ranked
Growth
Revenue growth (Higher is better)————————+17.0%FY2025 · SEC4th of 463rd74th+29.9%FY2025 · SEC3rd of 477th86th+726.7%FY2025 · SEC1st of 4100th100th+58.3%FY2025 · SEC2nd of 486th93rd————————+44.1%4 ranked
Revenue growth, 3 years a year (Higher is better)————————+2.3%FY2025 · SEConly one with it34th42nd————————————————————+2.3%—
Margins and returns
Gross margin (Higher is better)————————51.0%FY2025 · SEC3rd of 438th65th49.4%FY2025 · SEC4th of 435th63rd————————97.8%FY2025 · SEC1st of 497th99th59.0%FY2025 · SEC2nd of 451st73rd55.0%4 ranked
Operating margin (Higher is better)————————-470.4%FY2025 · SEC2nd of 47th2nd-958.8%FY2025 · SEC4th of 40th0th7.6%FY2025 · SEC1st of 469th62nd————-477.4%FY2025 · SEC3rd of 47th2nd————-473.9%4 ranked
Net margin (Higher is better)————————-443.9%FY2025 · SEC3rd of 47th2nd-946.0%FY2025 · SEC4th of 40th0th6.9%FY2025 · SEC1st of 473rd67th————-430.2%FY2025 · SEC2nd of 47th2nd————-437.1%4 ranked
Free cash flow margin (Higher is better)————————-278.9%FY2025 · SEC2nd of 412th3rd-787.3%FY2025 · SEC4th of 42nd1st3.2%FY2025 · SEC1st of 458th46th————-366.7%FY2025 · SEC3rd of 410th2nd————-322.8%4 ranked
Return on equity (Higher is better)————-55.4%FY2025 · SEC4th of 640th17th-25.1%FY2025 · SEC2nd of 658th26th-64.5%FY2025 · SEC5th of 636th15th22.3%FY2025 · SEC1st of 692nd87th-169.5%FY2025 · SEC6th of 613th6th-33.6%FY2025 · SEC3rd of 652nd22nd————-44.5%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————4.0×price Oct 22, 2026 · Market dataonly one with it5th3rd————————————4.0×—
Price to sales (Better neither way: ranked highest first)————————8.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price8.5×price Oct 20, 2026 · Market data3rd of 571st87th0.7×price Oct 22, 2026 · Market data5th of 511th20th67.6×price Sep 22, 2026 · Market data2nd of 593rd97th5.7×price Oct 30, 2026 · Market data4th of 560th80th96.7×price Oct 30, 2026 · Market data1st of 595th98th8.5×5 ranked
Price to book (Better neither way: ranked highest first)————1.1×price Oct 9, 2026 · Market data3rd of 520th22nd0.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price0.5×price Oct 20, 2026 · Market data4th of 56th6th1.3×price Oct 22, 2026 · Market data2nd of 526th32nd3.3×price Sep 22, 2026 · Market data1st of 554th65th0.4×price Oct 30, 2026 · Market data5th of 54th4th————1.1×5 ranked
Free cash flow yield (Higher is better)————-65.4%price Oct 9, 2026 · Market data5th of 614th5th-40.2%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-92.7%price Oct 20, 2026 · Market data6th of 68th3rd6.5%price Oct 22, 2026 · Market data1st of 691st74th-17.1%price Sep 22, 2026 · Market data3rd of 635th16th-63.8%price Oct 30, 2026 · Market data4th of 614th6th-9.0%price Oct 30, 2026 · Market data2nd of 645th22nd-40.4%6 ranked
Financial strength
Debt to equity (Lower is better)————————————————————0.0×FY2025 · SEConly one with it5th3rd————————0.0×—
Interest cover (Higher is better)————————————————————-13.3×FY2025 · SEConly one with it40th20th————————-13.3×—
Scorecard
Scorecard (Higher is better)——3 of 12FY2025 · Scorecard5th of 74 of 14FY2025 · Scorecard3rd of 75 of 17FY2025 · Scorecard2nd of 713 of 18FY2025 · Scorecard1st of 74 of 18FY2025 · Scorecard6th of 74 of 15FY2025 · Scorecard4th of 71 of 11FY2025 · Scorecard7th of 727% passed7 ranked
Valuation checks (Higher is better)——1 of 4FY2025 · Scorecard4th of 6——2 of 5FY2025 · Scorecard2nd of 65 of 5FY2025 · Scorecard1st of 60 of 5FY2025 · Scorecard5th of 62 of 5FY2025 · Scorecard2nd of 60 of 5FY2025 · Scorecard5th of 633% passed6 ranked
Growth checks (Higher is better)——0 of 2FY2025 · Scorecard6th of 72 of 5FY2025 · Scorecard3rd of 71 of 3FY2025 · Scorecard4th of 73 of 4FY2025 · Scorecard2nd of 71 of 3FY2025 · Scorecard4th of 70 of 2FY2025 · Scorecard6th of 71 of 1FY2025 · Scorecard1st of 733% passed7 ranked
Profitability checks (Higher is better)——0 of 3FY2025 · Scorecard3rd of 71 of 5FY2025 · Scorecard2nd of 70 of 4FY2025 · Scorecard3rd of 74 of 5FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard3rd of 70 of 4FY2025 · Scorecard3rd of 70 of 2FY2025 · Scorecard3rd of 70% passed7 ranked
Financial health checks (Higher is better)——1 of 2FY2025 · Scorecard2nd of 71 of 3FY2025 · Scorecard4th of 71 of 3FY2025 · Scorecard4th of 71 of 3FY2025 · Scorecard4th of 73 of 6FY2025 · Scorecard2nd of 72 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard7th of 733% passed7 ranked
Shareholder returns checks (Higher is better)——1 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard3rd of 61 of 2FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard3rd of 60 of 1FY2025 · Scorecard3rd of 60 of 1FY2025 · Scorecard3rd of 6——0% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——74.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 738.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 751.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 70.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 733.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 797.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 732.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 738.5%7 ranked
Institutions holding (Better neither way: ranked highest first)——652026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7682026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 752026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7682026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7687 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——-4.6 pp2026-Q2 against 2026-Q1 · 13F6th of 6-0.6 pp2026-Q2 against 2026-Q1 · 13F5th of 6+18.3 pp2026-Q2 against 2026-Q1 · 13F1st of 6+0.0 pp2026-Q2 against 2026-Q1 · 13F4th of 6——+4.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+8.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 6+2.4 pp6 ranked
Dividends
Shareholder yield (Higher is better)————————————12.4%FY2025 · SEConly one with it94th92nd————————————————12.4%—
Dividend per share (Better neither way: ranked highest first)————$0.00FY2025 · SEConly one with it——————————$0.00—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Otonomy: How market caps are worked out; PMV Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seer, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tonix Pharmaceuticals Holding Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vaxart, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rani Therapeutics Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; LENZ Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NRX Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Otonomy———
PMV Pharmaceuticals, Inc.———
Seer, Inc.-470.4%FY2025
7th percentile in Healthcaremedian -7.7%, 674 companies
2nd percentile in USAmedian 3.5%, 2,594 companies
Tonix Pharmaceuticals Holding Corp.-958.8%FY2025
0th percentile in Healthcaremedian -7.7%, 674 companies
0th percentile in USAmedian 3.5%, 2,594 companies
Vaxart, Inc.7.6%FY2025
69th percentile in Healthcaremedian -7.7%, 674 companies
62nd percentile in USAmedian 3.5%, 2,594 companies
Rani Therapeutics Holdings, Inc.———
LENZ Therapeutics, Inc.-477.4%FY2025
7th percentile in Healthcaremedian -7.7%, 674 companies
2nd percentile in USAmedian 3.5%, 2,594 companies
NRX Pharmaceuticals, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$59 M$119 M$178 M$237 M20102012201420162018202020222024Seer, Inc. $17 MTonix Pharmaceuticals Holding Corp. $13 MVaxart, Inc. $237 MRani Therapeutics Holdings, Inc. $2 M

Rank in the group

1st2nd3rd4th5th6th202020212022202320242025Seer, Inc.: 2nd of 3 in 2020Seer, Inc.: 1st of 3 in 2021Seer, Inc.: 1st of 2 in 2022Seer, Inc.: 1st of 3 in 2023Seer, Inc.: 2nd of 4 in 2024Seer, Inc.: 3rd of 6 in 2025Seer, Inc.Tonix Pharmaceuticals Holding Corp.: 2nd of 3 in 2023Tonix Pharmaceuticals Holding Corp.: 3rd of 4 in 2024Tonix Pharmaceuticals Holding Corp.: 4th of 6 in 2025Tonix Pharmaceuticals HoldVaxart, Inc.: 1st of 3 in 2020Vaxart, Inc.: 3rd of 3 in 2021Vaxart, Inc.: 2nd of 2 in 2022Vaxart, Inc.: 3rd of 3 in 2023Vaxart, Inc.: 1st of 4 in 2024Vaxart, Inc.: 1st of 6 in 2025Vaxart, Inc.Rani Therapeutics Holdings, Inc.: 3rd of 3 in 2020Rani Therapeutics Holdings, Inc.: 2nd of 3 in 2021Rani Therapeutics Holdings, Inc.: 4th of 4 in 2024Rani Therapeutics Holdings, Inc.: 5th of 6 in 2025Rani Therapeutics HoldingsLENZ Therapeutics, Inc.: 2nd of 6 in 2025LENZ Therapeutics, Inc.NRX Pharmaceuticals, Inc.: 6th of 6 in 2025NRX Pharmaceuticals, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearOtonomyPMV Pharmaceuticals, Inc.Seer, Inc.Tonix Pharmaceuticals Holding Corp.Vaxart, Inc.Rani Therapeutics Holdings, Inc.LENZ Therapeutics, Inc.NRX Pharmaceuticals, Inc.
2025——$17 MSEC3rd$13 MSEC4th$237 MSEC1st$2 MSEC5th$19 MSEC2nd$1 MSEC6th
2024——$14 MSEC2nd$10 MSEC3rd$29 MSEC1st$1 MSEC4th——
2023——$17 MSEC1st$8 MSEC2nd$7 MSEC3rd———
2022——$15 MSEC1st—$0 MSEC2nd———
2021——$7 MSEC1st—$1 MSEC3rd$3 MSEC2nd——
2020——$1 MSEC2nd—$4 MSEC1st$0 MSEC3rd——
2019————$10 MSEC———
2018————$4 MSEC———
2017————$9 MSEC———
2016————$9 MSEC———
2015————$25 MSEC———
2014————$69 MSEC———

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Otonomy#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • PMV Pharmaceuticals, Inc.PMVP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $113 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $113 M (Oct 9, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Seer, Inc.SEER · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $115 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $115 M (Aug 1, 2026) · revenue $17 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Tonix Pharmaceuticals Holding Corp.TNXP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $111 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $111 M (Oct 20, 2026) · revenue $13 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Vaxart, Inc.VXRT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $117 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $117 M (Oct 22, 2026) · revenue $237 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Rani Therapeutics Holdings, Inc.RANI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $110 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $110 M (Sep 22, 2026) · revenue $2 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • LENZ Therapeutics, Inc.LENZ · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $110 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $110 M (Oct 30, 2026) · revenue $19 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • NRX Pharmaceuticals, Inc.NRXP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $118 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $118 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Black Diamond Therapeutics, Inc.BDTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $108 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $108 M (Oct 26, 2026) · revenue $70 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Immunic, Inc.IMUX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $121 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $121 M (Oct 28, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Outlook Therapeutics, Inc.OTLK · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $119 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $119 M (Oct 30, 2026) · revenue $1 M (year to September 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • OnKure Therapeutics, Inc.OKUR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $107 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $107 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Foghorn Therapeutics Inc.FHTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $123 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.